Latham & Watkins Advises Ro in its US$500 Million Series D Financing

A New York-based emerging companies team advises the healthcare technology company in the transaction.

March 23, 2021

Ro, a healthcare technology company building a patient-centric healthcare system, has announced that it has raised US$500 million in its Series D funding round led by existing investors General Catalyst, FirstMark Capital, and TQ Ventures, with significant participation from existing investors SignalFire, Torch Capital, and BoxGroup as well as new investors Altimeter Capital, Baupost Group, Dragoneer Investment Group, ShawSpring Partners, Radcliff, and 776. The funding round values the New York City-based company at US$5 billion.

Latham & Watkins LLP represented Ro in the financing with an emerging companies team led by New York partner Peyton Worley, with associate Teddy Ellison.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.